Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Heinz Wiendl ^1* Frederik Barkhof ^2,3 Xavier Montalban ⁴ Anat Achiron ^5,6 Tobias Derfuss ⁷ Andrew Chan ⁸ Suzanne Hodgkinson ⁹ Alexandre Prat ¹⁰ Letizia Leocani ^11,12,13 Klaus Schmierer ^14,15 Finn Sellebjerg ^16,17 Patrick Vermersch ¹⁸ Hulin Jin ¹⁹ Anita Chudecka ²⁰ Andreas Kloetgen ¹⁹ Dongdong Lin ²¹ Lidia Gardner ²² Nicola De Stefano ²³

• ¹ Department of Neurology, University of Münster, Münster, Germany
• ² Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
• ³ Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, United Kingdom
• ⁴ Department of Neurology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Balearic Islands, Spain
• ⁵ Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Jerusalem, Israel
• ⁶ Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
• ⁷ Department of Neurology, University Hospital Basel, Basel, Switzerland
• ⁸ Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Bern, Switzerland
• ⁹ Ingham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, Australia
• ¹⁰ Department of Neurosciences, Université de Montréal, Montreal, Ontario, Canada
• ¹¹ Department of Neurology, University Vita-Salute San Raffaele, Milan, Lombardy, Italy
• ¹² Experimental Neurophysiology Unit, Scientific Institute IRCCS San Raffaele, Milan, Lombardy, Italy
• ¹³ Department of Neurorehabilitation Science, Casa di Cura Igea, Milan, Lombardy, Italy
• ¹⁴ The Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom
• ¹⁵ Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
• ¹⁶ Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark
• ¹⁷ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
• ¹⁸ Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, Nord-Pas-de-Calais, France
• ¹⁹ Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany
• ²⁰ Clinical Research Services, Cytel Inc., Geneva, Switzerland
• ²¹ Clinical Measurement Sciences, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, United States
• ²² Neurology & Immunology Medical Unit, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, United States
• ²³ Department of Medicne, Surgery and Neuroscience, University of Siena, Siena, Tuscany, Italy

• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Template continues on the next page 